
Additional Positive Data on LB-102 for the Treatment of Acutely Exacerbated Schizophrenia
LB Pharmaceuticals presented additional positive data from NOVA1, a phase 2 clinical trial of N-methyl amisulpride (LB-102) in patients with acutely exacerbated schizophrenia, at the 2025 Annual Congress of the Schizophrenia International Research Society …